深圳瀛晟生物医药

Yingsheng Biopharma is a clinical-stage biopharmaceutical company based in Shenzhen, China, specializing in the discovery and development of innovative small molecule therapeutics. The company leverages advanced structure-based drug design and fragment-based drug discovery platforms to target challenging biological pathways, particularly in oncology and metabolic diseases. Its lead candidate, YS-001, is a potent and selective USP1 inhibitor currently undergoing clinical evaluation for the treatment of advanced solid tumors. Yingsheng Biopharma aims to address significant unmet medical needs by developing high-quality, first-in-class or best-in-class medicines for global markets. The firm is supported by prominent Chinese venture capital firms and maintains a robust R&D facility in Shenzhen's Pingshan District.